Advertisement

Topics

Latest "Mifepristone Cushing Syndrome" News Stories

19:28 EST 12th February 2016 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 1,900+

Extremely Relevant

Orphan designation: Mifepristone, for the: Treatment of hypercortisolism (Cushing’s syndrome) of endogenous origin


Relevant

The "Abortion Pill" Still Available After 15 Years in the U.S.

This September marks the 15-year anniversary of the FDA's approval of the use of Mifepristone (also known as RU-486 or the "abortion pill"). Mifepristone is the first and only FDA-approved medication to provide women with a safe and effective non-surgical option to end an early pregnancy.

Corcept Therapeutics to Announce Second Quarter Financial Results and Corporate Update and Host Conference Call

MENLO PARK, CA -- (Marketwired) -- 07/29/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 5, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United S...


Stifel starts Strongbridge Biopharma at buy

Stifel has initiated coverage of Strongbridge Biopharma plc (NASDAQ:SBBP), formerly Cortendo plc, with a “buy” rating and a $21 target price. The stock closed at $7.49 on Monday. Strongbridge is an endocrinology-focused company, pursuing an acquisition model to build a diversified orphan-drug platform. “With a focus on rare endocrine diseases – Cushing’s syndrome and acromegaly [R...

Attorney Michael Cushing Settles Wrongful Death Suit

Michael Cushing, a personal injury attorney at Cushing Law Offices, recently settled a wrongful death lawsuit (Case No. 12 L 897) on behalf of the family of a woman who died from drug intoxication that included Fentanyl, and a combination of other drugs. Chicago, IL (PRWEB) January 05, 2016 The wrongful death lawsuit, Fred Saltzman, as Special Administrator of the Estate of Tenessa Vincent, decea...

Strongbridge's COR-003 vs. Corcept's Korlym for Treating Cushing's Syndrome

We received an inquiry from a reader that stated that a serious competitor had arisen to Corcept Therapeutics (CORT). Strongbridge BioPharma (SBBP) was allegedly promoted by Cramer as a promising company with a drug in Phase III for treating Cushing’s syndrome. The drug is called COR-003. Strongbridge is publicly traded on a Norwegian OTC Exchange; it is currently drumming up support for its ong...

Stonebridge's COR-003 vs. Corcept's Korlym for Treating Cushing's Syndrome

We received an inquiry from a reader that stated that a serious competitor had arisen to Corcept Therapeutics (CORT). Stonebridge BioPharma (SBBP) was allegedly promoted by Cramer as a promising company with a drug in Phase III for treating Cushing’s syndrome. The drug is called COR-003. Stonebridge is publicly traded on a Norwegian OTC Exchange; it is currently drumming up support for its ongoi...

Mifepristone: Additional Phase I/II data

Now Available! Lynch Syndrome: Get the Facts

Ask the Experts Series: A Family Affair: When Cancer Runs in the Family Lynch Syndrome: Get the Facts about this Hereditary Cancer Syndrome In this informative web chat, genetic counselor, Megan Myers, discusses what Lynch syndrome is, how you can learn if you have Lynch syndrome, and the things you can do to help prevent or reduce […] The post Now Available! Lynch Syndrome: Get the Facts ...

Corcept Therapeutics (CORT) Q3-2015 Update

On Thursday, November 5, 2015, Corcept Therapeutics (CORT) announced its results for Q3 2015 and held a conference call.

An Advance Guide to Corcept's Corporate Update

On Thursday, January 28, 2015, Corcept Therapeutics’ (CORT), Corcept will release preliminary Q4-2015 results and provide guidance and corporate update.  Since 2014, Corcept has been providing a major update in January. The conference call details are below:When:   5:00pm, January 28, 2015Phone:  1-888-771-4371 (USA) & 1-847-585-4405 (International)    ...

Corcept Therapeutics (CORT) - CORT125134 Phase I Results - Part I Overall Summary

On October 14, 2015, Corcept Therapeutics’ (CORT) VP of Research, Hazel Hunt, joined Quotient Clinical in a webinar and discussed the Phase I results for CORT 125134. The webinar is really a combination of the trial results plus a marketing promo for Quotient Clinical’s services.  We have split our discussion into two posts:1) This post will give an introduction to CORT125134 and summary ...

Additional Thoughts about Corcept's Early Phase I/II Results

On Monday morning, December 14, 2015, Corcept Therapeutics’ (CORT) CEO, Joe Belanoff, met with the BioWatch team at the Menlo Park HQ. Among other things, we were able to clarify a few thoughts regarding the poster presentation at the recent San Antonio Breast Cancer Symposium (SABCS). It involved early data on the use of eribulin + Korlym (mifepristone) to treat solid tumors, especially G...

Corcept (CORT) at the Edge of the Cliff

On Thursday, January 28, 2015, Corcept Therapeutics’ (CORT), Corcept released its preliminary Q4-2015 results with a corporate update and conference call. We created an advance guide to Corcept’s update and it was mostly on the mark. This isn’t to toot our horn but to underscore that management didn’t disclose any obvious surprises. There was no new information regarding ongoing cancer tri...

Corcept (CORT): Is it on a Slow Boat or Fast Boat?

On Thursday, January 28, 2015, Corcept Therapeutics’ (CORT), Corcept released its preliminary Q4-2015 results with a corporate update and conference call. We created an advance guide to Corcept’s update and it was mostly on the mark. This isn’t to toot our horn but to underscore that management didn’t disclose any obvious surprises. There was no new information regarding ongoing cancer tri...

Down Syndrome Research Untangles Therapeutic Possibilities for Alzheimer’s

More than five million Americans are living with Alzheimer’s disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid. In fact, patients with Down syndrome develop the abnormal protein at twice the rate. Results of a pilot study confirms the pathogenic role of beta amyloid in dementia as seen in both AD and Dow...

Corcept Therapeutics I: A New Look at its New Drugs - DRAFT 2.0

Quick BasicsIf you’re new to Corcept, then you might want to read this quick introduction to how its drug platform works: from Korlym to its next generation drugs. As you might recall, Korlym blocks the GR receptor, helping to correct unhealthy generation of cortisol. Cortisol is known as the “stress hormone”. It enables the body for “fight, fright, or flight”. This includes: autonomic p...

Down syndrome research untangles therapeutic possibilities for Alzheimer's

(University of California - San Diego) More than five million Americans are living with Alzheimer's disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid. In fact, patients with Down syndrome develop the abnormal protein at twice the rate. Results of a pilot study confirms the pathogenic role of beta amyloid i...

Accommodative deficits in Down's syndrome published by Dove Medical Press

(PRWEB) September 23, 2015 Clinical Optometry has published the review “ Accommodation deficit in children with Down Syndrome: Practical considerations for the Optometrist ”. As corresponding author Dr Julie-Anne Little says “Down syndrome is the most common cause of intellectual disabil...

Corcept Therapeutics (CORT) - CORT125134 Phase I Results - Part II Trial Overview & Our Thoughts

On October 14, 2015, Corcept Therapeutics’ (CORT) VP of Research, Hazel Hunt, joined Quotient Clinical in a webinar and discussed the Phase I results for CORT 125134. The webinar is really a combination of the trial results plus a marketing promo for Quotient Clinical’s services.  We have split our discussion into two posts:1) This post will give an introduction to CORT125134 and summary ...

Safety Complaints Lead FDA To Review Only Approved Nonsurgical Permanent Birth Control Option

Meanwhile, the Philadelphia Inquirer examines the impact of mifepristone, otherwise known as the abortion pill, over the last 15 years since its approval in the U.S.

Multimethod Testing Strategy May Benefit Patients with Lynch Syndrome

A new three-pronged approach may help better identify patients who have Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers, according to researchers at Baylor College of Medicine.

Full Post: Corcept Therapeutics (CORT) Q2 2015 Update &Conference Call

On Wednesday, August 5, 2015 Corcept Therapeutics (CORT) announced its results for Q2 2015 and held a conference call.

Molecular genetics and clinical features of Birt–Hogg–Dubé syndrome

Birt–Hogg–Dubé (BHD) syndrome is an inherited renal cancer syndrome caused by germline mutations in the FLCN gene on chromosome 17. Manifestations include benign cutaneous fibrofolliculomas, bilateral pulmonary cysts and spontaneous pneumothoraces, and kidney tumours. In this Review, Schmidt and Linehan provide an overview of BHD syndrome, discu...

Study identifies new link between Down syndrome and Alzheimer’s disease.

Down syndrome (DS) results from the trisomy of chromosome 21 in humans and is the most common cause of genetically defined intellectual disability. Among the various triplicate genes in DS is the one encoding for Ab precursor protein (APP), a transmembrane glycoprotein known for its association with the pathogenesis of Alzheimer disease (AD). This means that individuals with Down syndrome


Quick Search
Advertisement
 

News Quicklinks